Nanotechnology-Abetted Astaxanthin Formulations in Multimodel Therapeutic and Biomedical Applications | Journal of Medicinal Chemistry
![How can physical health be better addressed in people living with severe mental illnesses? | ResearchGate How can physical health be better addressed in people living with severe mental illnesses? | ResearchGate](https://i1.rgstatic.net/ii/profile.image/375942640881665-1466643118917_Q512/Hannah-Kirkwood-2.jpg)
How can physical health be better addressed in people living with severe mental illnesses? | ResearchGate
![Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in](https://www.ahajournals.org/cms/asset/08339483-5351-49f4-9caf-45ba5014d108/15ff1b.jpg)
Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in
![PDF) Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial PDF) Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial](https://i1.rgstatic.net/publication/335550663_Ticagrelor_in_patients_with_diabetes_and_stable_coronary_artery_disease_with_a_history_of_previous_percutaneous_coronary_intervention_THEMIS-PCI_a_phase_3_placebo-controlled_randomised_trial/links/5dab261aa6fdccc99d91d5b6/largepreview.png)
PDF) Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial
![References | Weight Management: State of the Science and Opportunities for Military Programs | The National Academies Press References | Weight Management: State of the Science and Opportunities for Military Programs | The National Academies Press](https://nap.nationalacademies.org/books/0309089964/gifmid/145.gif)
References | Weight Management: State of the Science and Opportunities for Military Programs | The National Academies Press
![Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in](https://www.ahajournals.org/cms/asset/eab7d797-1589-4839-acaa-71c8caa14f38/15ff2.jpg)
Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in
![Michael GONZALEZ | Professor (Full) | DSc, NMD, PhD, FANMA, FACN | University of Puerto Rico, Medical Sciences Campus, San Juan | Department of Human Development | Research profile Michael GONZALEZ | Professor (Full) | DSc, NMD, PhD, FANMA, FACN | University of Puerto Rico, Medical Sciences Campus, San Juan | Department of Human Development | Research profile](https://i1.rgstatic.net/ii/profile.image/1001884793991170-1615879357772_Q512/Michael-Gonzalez-24.jpg)
Michael GONZALEZ | Professor (Full) | DSc, NMD, PhD, FANMA, FACN | University of Puerto Rico, Medical Sciences Campus, San Juan | Department of Human Development | Research profile
![Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in](https://www.ahajournals.org/cms/asset/0f7b0cea-8b0f-4c9a-bebf-7c70c3d1d072/15ff1a.jpg)